Stability and antiviral activity against human cytomegalovirus of artemisinin derivatives

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 1, 2014, Pages 34-40

  Flobinus, Alyssa ^a   Taudon, Nicolas ^b,c   Desbordes, Marc ^b,c   Labrosse, Béatrice ^d,e   Simon, François ^a,d,f   Mazeron, Marie Christine ^a,d,f,g   Schnepf, Nathalie ^a,d,g  

^a SAINT LOUIS HOSPITAL   (France)

^b Aix Marseilles University   (France)

^c Centre National de Reference du Paludisme   (France)

^d INSERM   (France)

^e UNIVERSITÉ PARIS DIDEROT   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g laboratoire associé   (France)

Author keywords

Antiviral therapy; Drug susceptibility; Hplc; Metabolism

Indexed keywords

ARTEMISININ; ARTESUNATE; DIHYDROARTEMISININ;

ANTIVIRAL ACTIVITY; ARTICLE; CELL MEDIATED CYTOTOXICITY; CELL METABOLISM; CONTROLLED STUDY; CULTURE MEDIUM; DNA SYNTHESIS; DRUG HALF LIFE; DRUG STABILITY; FETAL CALF SERUM; FIBROBLAST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IN VITRO STUDY; NONHUMAN; VIRUS GENOME;

ANTIVIRAL THERAPY; DRUG SUSCEPTIBILITY; HPLC; METABOLISM;

ANTIVIRAL AGENTS; ARTEMISININS; BIOTRANSFORMATION; CULTURE MEDIA; CYTOMEGALOVIRUS; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS;

EID: 84890405658     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt346     Document Type: Article

References (36)

1. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23: 689-712.
2. Arav-Boger R, He R, Chiou CJ et al. Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers. PLoS One 2010; 5: e10370.
3. Chou S, Marousek G, Auerochs S et al. The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants. Antiviral Res 2011; 92: 364-8.
4. Efferth T, Marschall M, Wang X et al. Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. J Mol Med (Berl) 2002; 80: 233-42.
5. Efferth T, Romero MR, Wolf DG et al. The antiviral activities of artemisinin and artesunate. Clin Infect Dis 2008; 47: 804-11.
6. Kaptein SJ, Efferth T, Leis M et al. The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antiviral Res 2006; 69: 60-9.
7. Schnepf N, Corvo J, Pors MJ et al. Antiviral activity of ganciclovir and artesunate towards human cytomegalovirus in astrocytoma cells. Antiviral Res 2011; 89: 186-8.
8. Adjuik M, Babiker A, Garner P et al. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 2004; 363: 9-17.
9. Sinclair D, Donegan S, Isba R et al. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev 2012; issue 6: CD005967.
10. Lau PK, Woods ML, Ratanjee SK et al. Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection. Clin Infect Dis 2011; 52: 279.
11. Shapira MY, Resnick IB, Chou S et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis 2008; 46: 1455-7.
12. Morris CA, Duparc S, Borghini-Fuhrer I et al. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J 2011; 10: 263.
13. Dhingra V, Vishweshwar Rao K, Lakshmi Narasu M. Current status of artemisinin and its derivatives as antimalarial drugs. Life Sci 2000; 66: 279-300.
14. Jansen FH. The pharmaceutical death-ride of dihydroartemisinin. Malar J 2010; 9: 212.
15. KlaymanDL. Qinghaosu (artemisinin): an antimalarial drug fromChina. Science 1985; 228: 1049-55.
16. Tu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med 2011; 17: 1217-20.
17. Haynes RK, Krishna S. Artemisinins: activities and actions. Microbes Infect 2004; 6: 1339-46.
18. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol 2002; 32: 1655-60.
19. Meshnick SR, Yang YZ, Lima V et al. Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). Antimicrob Agents Chemother 1993; 37: 1108-14.
20. Berger TG, Dieckmann D, Efferth T et al. Artesunate in the treatment of metastatic uveal melanoma-first experiences. Oncol Rep 2005; 14: 1599-603.
21. Crespo-Ortiz MP, Wei MQ. Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol 2012; 2012: 247597.
22. Efferth T, Dunstan H, Sauerbrey A et al. The anti-malarial artesunate is also active against cancer. Int J Oncol 2001; 18: 767-73.
23. Singh NP, Panwar VK. Case report of a pituitary macroadenoma treated with artemether. Integr Cancer Ther 2006; 5: 391-4.
24. Qian RS, Li ZL, Yu JL et al. The immunologic and antiviral effect of qinghaosu. J Trad Chin Med 1982; 2: 271-6.
25. Stinski MF, Isomura H. Role of the cytomegalovirus major immediate early enhancer in acute infection and reactivation from latency. Med Microbiol Immunol 2008; 197: 223-31.
26. He R, Park K, CaiHet al. Artemisinin-derived dimer diphenyl phosphate is an irreversible inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 2012; 56: 3508-15.
27. He R, Mott BT, Rosenthal AS et al. An artemisinin-derived dimer has highly potent anti-cytomegalovirus (CMV) and anti-cancer activities. PLoS One 2011; 6: e24334.
28. Davis TM, Phuong HL, Ilett KF et al. Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria. Antimicrob Agents Chemother 2001; 45: 181-6.
29. Gautam A, Ahmed T, Batra V et al. Pharmacokinetics and pharmacodynamics of endoperoxide antimalarials. Curr Drug Metab 2009; 10: 289-306.
30. Miller RS, Li Q, Cantilena LR et al. Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: phase 1b study. Malar J 2012; 11: 255.
31. Schnepf N, Boiteau N, Petit F et al. Rapid determination of antiviral drug susceptibility of human cytomegalovirus by real-time PCR. Antiviral Res 2009; 81: 64-7.
32. Farenc C, Fabreguette JR, Bressolle F. Pk-fit: a pharmacokinetic/pharmacodynamic and statistical data analysis software. Comput Biomed Res 2000; 33: 315-29.
33. Augustijns P, D'Hulst A, Van Daele J et al. Transport of artemisinin and sodium artesunate in Caco-2 intestinal epithelial cells. J Pharm Sci 1996; 85: 577-9.
34. Wolf DG, Shimoni A, Resnick IB et al. Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res 2011; 90: 183-6.
35. Efferth T, Kaina B. Toxicity of the antimalarial artemisinin and its derivatives. Crit Rev Toxicol 2010; 40: 405-21.
36. Gordi T, Lepist EI. Artemisinin derivatives: toxic for laboratory animals, safe for humans? Toxicol Lett 2004; 147: 99-107.